Menu

Gilead Sciences

NASDAQ: GILD

Gilead Sciences develops and sells innovative medicines for HIV, viral hepatitis, cancer and inflammatory diseases. Its virology business, particularly HIV treatments and prevention medicines, is a major part of the company's pharmaceutical business, while its oncology business focuses on cancer therapies.

Sector
Health Technology
Industry
Biotechnology
Employees
17,000
Founded
1987

The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.

Gilead Sciences forecast

The forecast in short

tipranks records 23 analyst ratings on Gilead Sciences and summarises them as “Strong Buy”. Their average 12-month price target is USD 173.76 (3.38% Upside). Its tipranks score is 10 out of 10 — Outperform. These are tipranks’s figures as read on 2026-11-16, not CariBroker’s own view, and nothing here is advice to buy or sell.

Market cap

USD 209.59 B

≈ RM 857.36 B

Share price

USD 168.98

≈ RM 691.23 · 18 Nov close

#83World ranking

tipranks score

Outperform

10

Analyst ratings

Strong Buy

  • Buy1878%
  • Hold522%
  • Sell00%

tipranks’s own summary of the 23 ratings above.

12 months price forecast

USD 173.76 3.38% Upside

USD 115.01USD 145.92USD 176.82USD 207.73Past 12 months12 months forecastHighUSD 200AverageUSD 173.76LowUSD 1312025-112026-11

As tipranks publishes it. CariBroker has not recalculated any of it.

Financials

Q3 earnings, quarter ending Sep 29, 2026

MeasureQ3 20261-year change
Total revenue8.30B4.39% up
Net income2.43B11.27% up
Earnings per share1.9420.22% down
Net profit margin29.25%25.40% down
Free cash flow4.80B53.68% up
Debt-to-equity ratio2.0173.75% up

Revenue and net income, last 4 quarters

-$15.0B-$10.0B-$5.0B$0.0$5.0B$10.0BQ4 2025Q1 2026Q2 2026Q3 2026

Total revenueNet income

Analyst profiles: who made each call, and when

AnalystFromPositionTarget priceDated
Jasper HellwegArgus ResearchBuyUSD 1902026-11-11
Louise ChenScotiabankBuyUSD 2002026-11-10
Michael OkunewitchMaxim GroupBuyN/A2026-11-05
Brian AbrahamsRBC CapitalHoldUSD 1312026-11-05
Geoff MeachamCitiBuyUSD 1882026-11-04
Show all 24
AnalystFromPositionTarget priceDated
Evan SeigermanBMO CapitalBuyUSD 1842026-11-02
Daina GrayboschLeerink PartnersHoldUSD 1452026-11-02
Mohit BansalWells FargoBuyUSD 1902026-10-30
Joseph StringerNeedhamBuyUSD 2002026-10-30
Michael YeeUBSBuyUSD 1952026-10-30
Terence FlynnMorgan StanleyBuyUSD 1832026-10-30
Tyler Van BurenTD CowenBuyUSD 1752026-10-30
Chris SchottJ.P. MorganBuyUSD 1902026-10-30
Gregory RenzaTruist FinancialBuyUSD 1812026-10-30
Umer RaffatEvercore ISIBuyN/A2026-10-30
Carter GouldCantor FitzgeraldBuyUSD 1752026-10-29
Salveen RichterGoldman SachsHoldUSD 1552026-10-29
Emily FieldBarclaysHoldUSD 1452026-10-28
Brian SkorneyRobert W. BairdHoldUSD 1452026-10-27
Courtney BreenBernsteinBuyUSD 1602026-10-25
Tazeen AhmadBank of America SecuritiesBuyUSD 1722026-10-20
Morten HerholdtHSBCBuyUSD 1752026-09-10
Salim SyedMizuho SecuritiesBuyUSD 1702026-08-31
Akash TewariJefferiesBuyUSD 1802026-05-22

Investment strengths

Strong cash generation

Exceptionally strong operating and free cash flow provides financial resilience even when reported earnings are weak. This supports continued investment in research and development, funding for launches, debt servicing, and shareholder returns without relying solely on external financing.

HIV franchise momentum

The HIV franchise combines recurring chronic-treatment demand with strong product adoption and market leadership. Growth in Biktarvy, prevention products, and newer options such as Yeztugo gives Gilead a durable commercial base and supports continued cash generation.

Pipeline diversification

A broad pipeline across several therapeutic areas can reduce dependence on any single product or franchise over time. Continued development in oncology and inflammation, alongside multiple long-acting HIV programs, improves the company’s prospects for renewing growth.

People also ask

What is the 12-month price target for Gilead Sciences (GILD)?

tipranks publishes an average 12-month price target of USD 173.76 (3.38% Upside), as read on 2026-11-16. The highest target is USD 200 and the lowest is USD 131. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.

See tipranks’s own page ↗

How many analysts cover Gilead Sciences (GILD)?

tipranks records 23 analyst ratings: 18 buy, 5 hold and 0 sell, which it summarises as “Strong Buy”, as read on 2026-11-16.

See tipranks’s own page ↗

What is the tipranks score for Gilead Sciences (GILD)?

tipranks scores it 10 out of 10 and calls that “Outperform”, as read on 2026-11-16. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.

See tipranks’s own page ↗

Is this CariBroker’s own forecast for Gilead Sciences?

No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.

See tipranks’s own page ↗

Disclaimer

CariBroker provides information only and does not provide investment, financial or legal advice.

All investment ideas

Check another company

Search every bank, broker and alert list in one place